MARKET

ARMP

ARMP

Armata Pharmctcl
AMEX
2.620
+0.020
+0.77%
Closed 15:58 05/24 EDT
OPEN
2.590
PREV CLOSE
2.600
HIGH
2.670
LOW
2.580
VOLUME
5.31K
TURNOVER
0
52 WEEK HIGH
5.26
52 WEEK LOW
1.070
MARKET CAP
94.73M
P/E (TTM)
-1.1886
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at ARMP last week (0513-0517)?
Weekly Report · 6d ago
Weekly Report: what happened at ARMP last week (0506-0510)?
Weekly Report · 05/13 10:05
Armata Pharmaceuticals Price Target Maintained With a $7.00/Share by HC Wainwright & Co.
Dow Jones · 05/08 13:45
HC Wainwright & Co. Reiterates Buy on Armata Pharmaceuticals, Maintains $7 Price Target
Benzinga · 05/08 13:35
Analysts Offer Insights on Healthcare Companies: Valneva (VALN), Denali Therapeutics (DNLI) and Armata Pharmaceuticals (ARMP)
TipRanks · 05/08 10:50
Buy Rating Affirmed for Armata Pharmaceuticals Amid Progress and Strategic Financial Moves
TipRanks · 05/08 10:26
ARMP Stock Earnings: Armata Pharmaceuticals Misses EPS, Misses Revenue for Q1 2024
Armata Pharmaceuticals reported results for the first quarter of 2024. The company reported earnings per share of -69 cents. Armata reported revenue of $966,000. This was 12.18% worse than the analyst estimate for revenue of $1.10 million.
Investorplace · 05/08 03:54
ARMATA PHARMACEUTICALS, INC. - Form 10-Q for the Quarterly Period Ended March 31, 2024
Press release · 05/08 00:43
More
About ARMP
Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its bacteriophage-based technology. Th Company is engaged in developing and advancing a pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. Its two lead candidates addresses both chronic and acute bacterial infections. The Company's first lead candidate focused primarily on chronic bacterial infections is the clinical phage candidate for Pseudomonas aeruginosa. In parallel, it has an acute bacterial infection clinical development plan focused on Staphylococcus aureus bacteremia, a difficult-to-treat and often life-threatening infection.

Webull offers Armata Pharmaceuticals Inc stock information, including AMEX: ARMP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ARMP stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ARMP stock methods without spending real money on the virtual paper trading platform.